Product Images Erlotinib

The text provided does not contain useful information as it appears to be a screenshot of a graph with numbers and symbols that cannot be interpreted. Therefore, the description cannot be generated.*

The text contains a Figure 2 showing Kaplan-Meier curves for overall survival of patients by treatment group in Study 3. The survival probability is plotted on the y-axis and overall survival in months is plotted on the x-axis. It also includes a chart with the number of patients at risk in both treatment groups, Picebo and Edoib.*

The text describes a figure showing Kaplan-Meier curves for overall survival rates of patients in Study 4, categorized by their treatment group. The graph displays the survival probability graphed against Overall Survival in months. The numbers at the bottom of the graph show the total number of patients that were at risk for each treatment group.*

The text is describing a Kaplan-Meier curve for overall survival in a clinical trial called "Study 5" of a medication at a 100 mg dosage. The x-axis indicates the overall survival in months, and the y-axis indicates the survival probability. The graph includes two lines, one for the placebo group and one for the group that received erlotinib, and displays the number of patients at risk during the study.*

Erlotinib is a medication available in tablet form. It is manufactured by Shilpa Medicare Limited and distributed by Armas Pharmaceutical, Inc. The tablets contain 150mg of erlotinib free base. The usual dosage and complete prescribing information can be found in the enclosed package insert. Storage of the medication should be at 25°C (77°F) with excursions permitted to 15°-30°C (59°-86°F). The medication comes in a package of 30 tablets and the NDC number is 72485-219-30.*